CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (157,781)	$ (60,575)
Adjustments to reconcile net loss to cash flows from operating activities:
Depreciation and amortization	63,815	72,719
Share-based compensation expense	74,473	46,240
Deferred income taxes	(35,073)	(18,731)
Excess tax benefit from share-based compensation	(32,817)	(22,444)
Gain on the Gainesville Transaction	(9,937)
Increase in fair value of contingent consideration	(2,700)
Gain on sale of property, plant and equipment	(586)	(11,942)
Gain on sale of investment of Acceleron Pharma Inc.		(15,296)
Other non-cash charges	66	9,921
Changes in assets and liabilities:
Receivables	(1,955)	(9,538)
Inventory, prepaid expenses and other assets	13,542	(17,774)
Accounts payable and accrued expenses	46,291	25,103
Deferred revenue	(1,172)	(607)
Other long-term liabilities	1,059	420
Cash flows used in operating activities	(42,775)	(2,504)
CASH FLOWS FROM INVESTING ACTIVITIES:
Additions of property, plant and equipment	(36,729)	(20,326)
Proceeds from the sale of equipment	181	14,361
Net proceeds from the Gainesville Transaction	50,267
Purchases of investments	(350,157)	(550,102)
Sales and maturities of investments	335,169	246,540
Cash flows used in investing activities	(1,269)	(309,527)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from the issuance of ordinary shares, net		248,406
Proceeds from the issuance of ordinary shares under share-based compensation arrangements	31,633	27,431
Excess tax benefit from share-based compensation	32,817	22,444
Employee taxes paid related to net share settlement of equity awards	(17,065)	(12,566)
Principal payments of long-term debt	(5,064)	(5,064)
Cash flows provided by financing activities	42,321	280,651
NET DECREASE IN CASH AND CASH EQUIVALENTS	(1,723)	(31,380)
CASH AND CASH EQUIVALENTS - Beginning of period	224,064	167,562
CASH AND CASH EQUIVALENTS - End of period	222,341	136,182
Non-cash investing and financing activities:
Purchased capital expenditures included in accounts payable and accrued expenses	2,409	$ 691
Fair value of warrants received as part of the Gainesville Transaction	2,123
Fair value of contingent consideration received as part of the Gainesville Transaction	$ 57,600